Indomethacin, a common nonsteroidal anti-inflammatory drug, has been shown to enhance radiation-mediated cellkilling effect through the activation of p38 mitogenactivated protein kinase (MAPK). We found that indomethacin strongly reduced the basal level of extracellular signal-regulated kinases 1 and 2 (ERK1/2) in HT-29 human colon carcinoma cells. The inhibition of ERK1/2 by indomethacin was only observed in cells with high basal activities of ERK1/2 such as HT-29 cells, but not in cells with low basal activities, such as HeLa. Cell cycle analysis of HT-29 cells exposed with indomethacin showed a partial G1/S arrest and slow DNA synthesis. However, the treatment with NS398, a specific COX-1/2 inhibitor, failed to show any effect on cell cycle, indicating that the inhibition of COX-1/2 is not responsible for cell cycle arrest. Since U0126, a specific inhibitor for MEK1/2, also induced a partial G1/S arrest, the G1/S arrest induced by indomethacin is, at least in part, caused by the inhibition of ERK1/2. Cell proliferation of HT-29 was inhibited by the treatment of U0126 but not in HeLa cells, and the treatment of HT-29 cells with U0126 enhanced radiation sensitivity possibly due to the accumulation of cells in G1 phase. We found that 17-allylamino-17-demethoxygeldanamycin, a geldanamycin delivative, radiosensitized HT-29 cells at a relatively low dose of irradiation, and indomethacin and U0126 further enhanced this effect. Therefore, tumor cells with elevated ERK1/2 activity can be effectively sensitized to radiation treatment by a combinational inhibition of HSP90 and MAPK activity.
Introduction
Radiation therapy is one of the major cancer treatment regimens in clinic. Although recent technologies such as intensity-modulated radiation therapy (IMRT) and gamma knife (stereotactic radiosurgery), which precisely aim to target tumor, greatly reduced the damage to normal tissues, delivery of high-dose ionizing radiation (IR) is still limited due to the damage to surrounding normal tissues (Purdy, 2002; Gerosa et al., 2003) . One possible solution for this problem is to preferentially sensitize tumor cells to IR, which could reduce the dose of IR in treatments.
The mitogen-activated protein kinases (MAPKs) are serine/threonine kinases that are important mediators of the reaction of cells to a variety of stimuli by transducing extracellular signals into cellular responses (Seger and Krebs, 1995) . There are two different categories of MAPKs: one is the stress-inducible kinases (Morrison and Davis, 2003) such as p38 and Jun aminoterminal kinase (JNK), the other group is conventional MAPKs, extracellular signal-regulated kinase (ERK)1/ 2, which are selectively activated by growth hormones such as epidermal growth factor (EGF) or by the mutations in Ras or Raf proto-oncogene in tumor cells (Chong et al., 2003) . It has been demonstrated that the activation of ERK1/2 in neoplastic cells results in phosphorylation of downstream effectors that inhibit apoptosis and stimulate cell proliferation. The activation of epidermal growth factor receptor (EGFR) by EGF or transforming growth factor (TGF)-a plays an important role in the growth of both normal and neoplastic intestinal epithelial cells (Sheng et al., 2001b) . Indeed, the activation of ERK1/2 is required for the growth-promoting effect of TGF-a (Matsuura et al., 1999) and activated Ras (Sheng et al., 1998 (Sheng et al., , 2001a in intestinal epithelial cells. Furthermore, the targeted disruption of EGFR in a Min mouse which carries a germ-line mutation of adenomatous polyposis coli (APC) strongly suppresses the incidence of intestinal polyps, suggesting that the activation of the EGFRdependent MAPK pathway is required for adenoma formation (Roberts et al., 2002) . EGFR tyrosine kinase inhibitors and antagonistic anti-EGFR antibodies are currently being used or tested clinically for the treatment of cancers including colorectal cancers (Barnard, 2001; O'Dwyer and Benson, 2002) .
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin are potent inhibitors of cyclooxygenase 1 and 2 (COX-1, -2), which are major effectors of inflammation through the biosynthesis of prostaglandins (Brooks et al., 1999) . Recently, NSAIDs have been found to be effective in preventing colorectal cancers. Epidemiological evidence has suggested that regular use of NSAIDs such as aspirin or sulindac reduces the risk for colorectal cancer and lowers the prevalence of colorectal adenomas (Marnett, 1995) . The effect of these drugs seems to be related to the inhibition of COX activities which promote angiogenesis (Jones et al., 1999) . The selective COX-2 inhibitor celecoxib has been reported to cause a modest regression of colonic adenomas in patients with familial adenomatous polyposis (Steinbach et al., 2000) .
HSP90 is a molecular chaperon involved in mediating cellular response to stress by regulating the conformation, stability, and function of key client proteins for signal transduction, cell cycle, growth control, and apoptosis (Mimnaugh et al., 1996; An et al., 1997; Stancato et al., 1997; Obermann et al., 1998; Maloney and Workman, 2002) . A bensoquinone ansamycin antibiotic geldanamycin (GA), along with its clinically used analogue 17-allylamino-17-demethoxygeldanamycin (17-AAG), binds to HSP90 and inhibits its function by masking its ATP-binding site (Munster et al., 2001; Neckers, 2002) . Since the inhibition of HSP90 by GA and 17-AAG results in the inhibition of several cellular survival factors, including RAF-1, AKT, ERK1, GLUT-1, HER-2/neu, LYN, and ERBB2, these drugs show significant anticancer properties (Neckers, 2002) . A recent study revealed that 17-AAG actually has higher affinity to HSP90 expressed in tumor cells than that expressed in normal cells, because HSP90 expressed in tumor cells is in a highly active state (Kamal et al., 2003) . The treatment of 17-AAG has also been shown to sensitize tumor cells to IR exposure (Bisht et al., 2003; Machida et al., 2003; Russell et al., 2003) . These features further add the value of 17-AAG as a potent chemotherapy agent.
A high concentration (>0.5 mM) of indomethacin has been shown to sensitize HeLa cells to IR through the activation of p38 MAPK, which leads to the inhibition of NF-kB (Bradbury et al., 2001) . We investigated the effect of indomethacin on the activities of MAPKs in HT-29, human colon carcinoma cells. We found that ERK1/2 are highly active in these cells and that indomethacin effectively inhibits their activities and sensitizes cells to irradiation. A selective MEK1/2 inhibitor, U0126, was also found not only to inhibit the growth of HT-29 cells but also to sensitize them to IR treatment. At the clinically relevant dose of irradiation, where the effects of indomethacin and U0126 are moderate, the combination treatment with 17-AAG clearly enhances their effect to sensitize cells to irradiation.
These results suggest that the inhibition of a conventional MAPK pathway together with HSP90 function is an effective approach to sensitize certain types of tumor cells to IR treatment, especially for those that are aggressively growing due to the autocrine growth hormone production or the mutations in ras or raf gene.
Results

Indomethacin induces ERK1/2 activities in serum-starved HeLa cells
A high concentration (>500 mM) of indomethacin has been shown to activate p38 MAPK and sensitize HeLa cells to IR. We investigated the effect of indomethacin on another MAPK, ERK1/2. HeLa cells were serum starved for 24 h and exposed to indomethacin. Activated ERK1/2 were identified by Western blotting with phospho-ERK1/2-specific antibody. Active ERK1/2 level was slightly increased by the treatment with indomethacin in time-dependent manner ( Figure 1a ). Increased active ERK1/2 was obvious after 1 h of incubation with indomethacin. Phorbol ester (4 beta-12-O-tetradecanoylphorbol-13-acetate (TPA)) and 10% FCS treatments induced the activation of ERK1/2 in HeLa cells as expected. Addition of indomethacin in culture media showed little effect on these induced ERK1/2 activities in HeLa cells (Figure 1b) . 
Indomethacin inhibits G1/S transition by inhibiting ERK1/2 activities
The activation of conventional MAPKs such as MEK1/ 2 and ERK1/2 induces the activation of G1 cyclins. Therefore, we analysed cell cycle progression of HT-29 cells after exposure to indomethacin. HT-29 cells were treated with indomethacin (500 mM) for 1 h, followed by 30 min labeling with bromodeoxyuridine (BrdU). BrdUchase experiments were conducted up to 12 h in the presence of drug. Labeled cells were detected by fluorescein isothiocyanate (FITC)-conjugated antiBrdU antibody, counterstained with propidium iodide, and cell cycle distribution was measured by FACS analysis (Figure 3a ). Indomethacin treatment caused S-phase delay in BrdU-positive cells (filled arrows), indicating that indomethacin inhibits DNA synthesis in S phase. Indomethacin also reduced BrdU-negative cells in S phase (open arrows), indicating that indomethacin partially inhibits S-phase entry from G1. Another NSAID, resveratrol (50 mM), also showed a partial G1 block and more severe S-phase delay (filled arrows). NS398, a selective COX-2 inhibitor, however, did not show any effects on cell cycle distribution up to 12 h after exposure. These results indicate that the inhibition of COX-2 activity by these NSAIDs is not responsible for the G1 block or S-phase delay in HT-29 cells. On the other hand, treatment with U0126, a specific MEK1/2 inhibitor, showed reduced BrdU-negative cells in S phase (open arrows), but does not delay the progression of BrdU-positive cells through S phase. Therefore, indomethacin-induced G1 block is, at least partially, caused by the inhibition of ERK1/2.
Indomethacin-induced inhibition of DNA synthesis is enhanced by IR treatment
The effect of indomethacin on the cell cycle distribution of HT-29 cells after irradiation was analysed. HT-29 cells were treated with 500 mM indomethacin or vehicle (ethanol) for 1 h, and irradiated with 10 Gy. Cells were pulse labeled with BrdU for 30 min and cell cycle distribution was determined by FACS analysis at 0, 6, and 12 h after irradiation ( Figure 3b ). Irradiation induced the inhibition of DNA synthesis demonstrated as S-phase delay in BrdU-positive cells, and caused G2 arrest afterwards in ethanol-treated control cells (filledarrows). In agreement with previous studies, HT-29 cells Since indomethacin effectively inhibits the basal ERK1/2 activities in HT-29 cells and therefore inhibits cell growth, we tested whether the inhibition of ERK1/2 induces radiosensitization in HT-29 cells. We also tested the radiosensitization effect of blockage of ERK1/2 activities in HeLa cells. Cells were treated with a specific MEK1/2 inhibitor U0126 (10 mM) for 36 h and irradiated. Cells were then replated for clonogenic colonyforming assay (Figure 6 ). The treatment with U0126 for 36 h did not reduce cell survival. However, HT-29 cells treated with U0126 became more sensitive to IR than control cells, with a dose-modifying factor of 1.49 at the survival level of 0.1. HeLa cells, however, were not sensitized to IR by U0126 treatment. These results showed that U0126 treatment not only inhibited the growth of HT-29 cells but also sensitized to IR, whereas U0126 did not show any effect on HeLa cell growth or radiosensitivity where low basal level ERK1/2 activities are observed.
Cooperative effect of indomethacin or U0126 with 17-AAG on radiosensitization
Radiosensitization effects of indomethacin and U0126 in HT-29 cells are evident in a relatively high dose of irradiation, such as 6 Gy; however, their effects are moderate when cells are exposed to a clinically relevant dose, such as 2 Gy (Figure 6 ). A GA derivative 17-AAG has been shown to have a radiosensitization effect in cervical tumor cells, gliomas and prostate carcinomas (Neckers, 2002 ). Thus, we tested whether 17-AAG sensitizes HT-29 cells to radiation, and its cooperative effect with indomethacin and U0126 on the cell-killing effect, together with clinically relevant dose of irradiation. The treatment with 17-AAG (0.1 mM) killed 47% of HT-29 cells, whereas irradiation ( Gy) alone killed 21% of cells (Figure 7 ). When cells were irradiated with 2 Gy in the presence of 17-AAG, cell survival was reduced to 32%, indicating that 17-AAG radiosensitized HT-29 cells (P ¼ 0.00988). Combination with indomethacin and U0126 treatments further reduced cell survival to 24 and 22%, with P-values of 0.0466 and 0.0464, respectively. These results indicate that the radiosensitization effects of indomethacin and U0126 at a clinically relevant dose of irradiation are enhanced by the combined treatment with 17-AAG.
Discussion
NSAIDs are potent inhibitors of cyclooxygenases that are a major cause of inflammation through the biosynthesis of prostaglandins (Brooks et al., 1999) . Epidemiological evidence has suggested that the regular use of NSAIDs such as aspirin or sulindac reduces the risk for colorectal cancer and lowers the prevalence of colorectal adenomas (Marnett, 1995) . The effect of these drugs seems to be related to the inhibition of COX activities which promote angiogenesis (Jones et al., 1999) .
Indomethacin weakly induced ERK1/2 activities in serum-starved HeLa cells after 1 h of exposure. These results suggest that the activation of ERK1/2 is not a direct effect of indomethacin on MAPK pathway. NSAIDs such as indomethacin or salicylate have been shown to induce the stress-inducible p38 MAPK. The activation of p38 causes the inhibition of NF-kB, possibly by preventing the dissociation of I-kB from NF-kB (Bradbury et al., 2001 ). Therefore, it is possible that unidentified kinases that are activated as a consequence of indomethacin treatment activate ERK1/2. On the other hand, the inhibition of ERK1/2 activities in HT-29 cells by indomethacin is a rapid response; therefore, indomethacin likely inhibits the member(s) of MAPK pathway in HT-29 cells.
Cell cycle analyses revealed that indomethacin and resveratrol affect the cell cycle progression in two phases: the inhibition of DNA synthesis and the blockage of S-phase entry. Since a selective COX-2 inhibitor, NS393, failed to show any effects on cell cycle progression in HT-29 cells, the inhibitory effect of indomethacin on COX-2 is not responsible for the inhibition of cell cycle progression by these NSAIDs. It is noteworthy to point out that NS398 has a potential target(s) other than COX-2 in cells. A recent study revealed that NS398 reduced HIF-1a and HIF-1 transcriptional activity in COX-2-dependent and -independent mechanisms (Zhong et al., 2004) . Resveratrol has been shown to inhibit DNA synthesis by inhibiting ribonucleotide reductase, the enzyme which provides proliferating cells with deoxyribonucleotides required for DNA synthesis (Fontecave et al., 1998) , and by directly inhibiting DNA polymerases a and d (Stivala et al., 2001) . We found that the inhibition of DNA synthesis induced by indomethacin was enhanced by IR, suggesting that indomethacin may inhibit DNA synthesis by a mechanism different from that induced by IR. The inhibitory effect of indomethacin on DNA synthesis still needs to be elucidated. The G1 arrest function of indomethacin in HT-29 cells is due to, at least partially, the inhibition of ERK1/2 activities, since a selective inhibitor for ERK1/2, U0126, also showed a partial G1 block. The activation of ERK1/2 plays critical roles on G1/S transition. Active ERK1/2 induces the accumulation of cyclin D1, a critical cyclin for G1/S transition (Weber et al., 1997; Phillips-Mason et al., 2000) , translocation of CDK2 to the nucleus (Keenan et al., 2001) , and phosphorylation of CDK2 at Thr-160 (Lents et al., 2002) , which is required for active CDK2-cyclin E complex. Resveratrol has been shown to induce the degradation of cyclin D1 in human colorectal SW480 cells (Wolter et al., 2001; Joe et al., 2002) . Thus, the partial G1 block induced by resberatrol in HT-29 cells is likely due to lowered cyclin D1 in HT-29 cells.
The activation of ERK1/2 also leads to phosphorylation of several downstream effectors, including protein kinases and transcription factors responsible for regulating genes that enhance cell proliferation, and protect them from apoptosis. ERK1/2-dependent phosphorylation of transcription factors, including c-FOS, c-JUN, and c-MYC, has been directly linked to promotion of Figure 7 Combined effect of indomethacin, U0126, and 17-AAG on HT-29 cell survival treated with a clinically relevant dose of irradiation. HT-29 cells plated in 6 cm dishes were treated with 17-AAG (0.1 mM) for 16 h, then treated with indomethacin (1 mM) for 1 h. Cells were irradiated with Gy and cell survival was determined as described in Materials and methods. For U0126 treatment, cells were treated with U0126 (10 mM) together with 17-AAG for 16 h, and then irradiated. Combinations of treatments are shown in the figure as ( þ ) treated or (À) not treated. Mean values of the results of three independent experiments are shown, with error bars of standard deviations. The cell survivals (%) with treatment are: IR (7971.7), indomethacin (10873.5), U0126 (87711.5), 17-AAG (53710.4), 17-AAG þ indomethacin (5677), IR þ indomethacin (93710.4), IR þ U0126 (8478.8), IR þ 17-AAG (3275.3), IR þ 17-AAG þ indomethacin (2473.5), and IR þ 17-AAG þ U0126 (2275.5). Statistical analyses between two groups were performed with an unpaired Student t-test and probability (P) values were calculated. *P ¼ 0.00988, **P ¼ 0.0466, ***P ¼ 0.0464 cell proliferation (Lewis et al., 1998; Cobb, 1999) . A selective MEK1/2 inhibitor U0126 inhibited the growth of HT-29 cells in culture (Figure 4) , indicating that the inhibition of the ERK1/2 signaling pathway alone is sufficient to block the growth of certain tumors. Although we did not observe massive apoptosis in HT-29 cells with 1 h treatment of indomethacin or U0126, prolonged incubation (72 h) of HT-29 cells with indomethacin has been shown to induce apoptosis (Shiff et al., 1996) . ERK1/2 are known to regulate cellular apoptotic event. ERK1/2-dependent phosphorylation of the proapoptotic protein BAD at serine 112 results in dissociation of BAD from BCL-2 and BCL-X L , allowing these antiapoptotic proteins to prevent mitochondrial-dependent apoptosis (Scheid et al., 1999) . Inhibition of ERK1/2 activity by U0126 has been shown to block EGF-induced phosphorylation of BAD (Ser112) (Rice et al., 2003) . NSAIDs including indomethacin have also been shown to affect other BCL-2 family members. Indomethacin and sulindac sulfide inhibit expression of the antiapoptotic BCL-X L protein in colon cancer cells by unknown mechanisms (Zhang et al., 2000) . As ERK1/2 can regulate BCL-2 and BCL-XL protein expression, it is possible that NSAIDs downregulate the expression of these proteins by their ability to inhibit ERK1/2 signaling.
We found that the inhibition of MEK1/2 by U0126 not only inhibited cell growth of HT-29 cells but also sensitized them to IR-induced cell killing. Since U0126 treatment did not affect cell growth, cell cycle distribution, or radiosensitivity in HeLa cells, the proliferation of HT-29 cells strongly depends on the activation of MAPK pathway. Similarly, a human prostate cancer cell line DU145 has been reported to be radiosensitized by MEK1/2 inhibition (Hagan et al., 2000) . Since indomethacin inhibits ERK1/2 activities in HT-29 cells as does U0126, it is reasonable to assume that the induced G1 arrest is the cause of radiosensitization in HT-29 cells. In some cell lines with active Ras and wildtype p53, it has also been suggested that MEK inhibition leads to radiosensitization through p53 induction (Ries et al., 2000) . The inhibition of growth-regulating kinases that play critical roles in growth of particular types of cancer cells seems to have a role in sensitizing cancer cells to IR. The overexpression of EGFR, which is frequently seen in cancers, potentially leads to increased PI3K activity and the inhibition of PI3K by LY294002 sensitized the T24 cells to IR (Gupta et al., 2001 ). An association between EGFR and clinical radioresistance has been reported in patients with head and neck cancers (Maurizi et al., 1996) and astrocytic gliomas (Zhu et al., 1996) .
Owing to the potential limitations of focusing on an individual molecule or pathway, it would appear that targeting multiple stress-response pathways simultaneously should lead to more effective radiosensitization. The radiosensitization effects of indomethacin and U0126 are not potent with the clinically relevant dose of irradiation. Combined treatment of indomethacin or U0126 together with 17-AAG further enhances the sensitivity of cells to radiation. Several survival factors (AKT1, ERK, HER-2/neu, RAF-1, and LYN) which protect against IR-induced cell death have been previously shown to be subjected to 17-AAG-or GAinduced degradation (Neckers, 2002) . Therefore, it is likely that the cooperative effect of 17-AAG together with indomethacin or U0126 on radiosensitization is due to the inhibition of more than one survival factor, including ERK1/2.
An intriguing aspect of using 17-AAG as a radiosensitizing agent is the differential effect in normal and tumor cells. In Phase I clinical trial, 17-AAG is well tolerated in patients even though HSP90 is also present in normal cells. This is because 17-AAG binds to HSP90 with 100 times higher affinity in tumor cells, where HSP90 is in an activated state as a part of the multichaperon complex (Kamal et al., 2003) . There is another potential benefit for using 17-AAG. Eustace et al. (2004) found that HSP90a but not b isoform is expressed extracellularly and binds to matrix metalloproteinase 2 (MMP2) to activate MMP2 activity, and thus supports invasiveness of tumor cells. Since the inhibition of extracellular HSP90a decreases both MMP2 activity and invasiveness, anti-HSP90 drugs might decrease invasiveness without the concerns inherent in inhibiting intracellular HSP90 in addition to its radiosensitization effect.
Our results suggest that the inhibition of a conventional MAPK pathway is an effective approach to sensitize certain types of tumor cells to IR treatment, especially for those that are aggressively growing due to the constitutively activated ERK1/2. Furthermore, the radiosensitization effect in these cells is enhanced by a combined treatment with 17-AAG.
Materials and methods
Cell culture, chemicals, and antibodies Saos2, A431, H1299, HT-29, MCF7, and HeLa cells were obtained from the American Type Culture Collection (Manassas, VA, USA), and HepG2 and HL460 were gifts from Dr Mike Freeman (Vanderbilt University Medical School). Cells were maintained in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% FCS in a humidified incubator atmosphere of 5% CO 2 -95% air. Indomethacin, resveratrol, propidium iodide, and BrdU were obtained from Sigma Chemical Co. (St Louis, MO, USA). NS398 and U0126 were obtained from Calbiochem (San Diego, CA, USA). 17-AAG is a gift from Dr David Gius (NCI, NIH). Primary antibodies against phosphorylated ERK1/2 and total ERK1/2 were from Cell Signaling Technology (Beverly, MA, USA). Anti-BrdU was obtained from Becton Dickinson (San Jose, CA, USA).
Cell growth and clonogenic survival assay
Clonogenic cell survivals were measured as described previously (Bradbury et al., 2001) . Briefly, cells were grown in 100 mm plates until they reached 50% confluence. After attaining sufficient growth, drug treatments were initiated, followed by exposure to IR. Immediately after IR exposure, cells were re-plated into 60 mm dishes and allowed to grow for 2 weeks. Colonies were stained with 0.05% crystal violet in 20% ethanol/0.37% formaldehyde solution, and those containing more than 50 cells were counted.
Western blotting
Cells were grown in six-well plates until semiconfluent. Serum starvation was performed for 16 h by culturing HeLa cells in DMEM without FCS. Cells were directly lysed in a well with NP-40 lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% NP-40) supplemented with proteinase inhibitors (0.5 mg/ml aprotinin, 0.5 mg/ml leupeptin, 0.7 mg/ml pepstatin A) and with phosphatase inhibitors (2 mM sodium pyrophosphate, 50 mM NaF, 5 mM b-glycerophosphate, 1 mM sodium orthovanadate). Lysates were subjected to a brief sonication followed by a centrifugation (14 000 Â g) for 10 min, and supernatants were collected. Protein concentrations were determined by Bradford method (BioRad, CA, USA). Total cell lysates were separated by SDS-PAGE, and transferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA). Membranes were incubated with primary antibodies, followed by secondary antibodies conjugated with alkaline phosphatase. Signals were detected using the Western Star system (Applied Biosystems, CA, USA).
Cell cycle analysis
Experimental cell cultures were set up 48 h before the start of study, at a concentration of 1 Â 10 5 cells per 100 mm dish. BrdU-pulse-chase studies were conducted using procedures previously described in detail (Menon et al., 2003) . Briefly, 1 h after the start of drug treatment, cells were labeled with 10 mM BrdU for 30 min by adding 150 ml of 1 mM stock solution into the flasks. At the completion of labeling, cells were washed twice and covered with 15 ml of BrdU-free medium supplemented with 20 mM each of thymidine and cytidine, and an equiconcentration of the drugs. Cells from one of the dishes were harvested immediately by trypsinization and fixed in 70% ethanol. Cells in the remaining dishes were incubated for the times indicated, and then they were harvested and fixed. The ethanol-fixed cells were washed in phosphate-buffered saline (PBS) and digested with pepsin (0.4 mg/ml in 2 N HCl) for 30 min to obtain nuclei with partially denatured DNA.
Following indirect immunostaining of BrdU incorporated in DNA with mouse anti-BrdU antibody and FITC-conjugated goat anti-mouse IgG, the nuclei were digested with RNase A (100 mg/ml) and stained with propidium iodide (PI, 20 mg/ml) for their DNA content. Nuclei were analysed by a FACS 440 flow cytometer (Becton Dickinson) interfaced to a CICERO/ CYCLOPS data acquisition/analysis system (Cytomation, Ft. Collins, CO, USA). The fluorescence dyes were excited with 488 nm line of an argon ion laser (Coherent, Mountain View, CA, USA) at 300 mW, and green FITC fluorescence was detected though a 530-nm band-pass filter, while red PI fluorescence was detected through a 640-nm long-pass filter. In all, 20 000 events were acquired per sample as list mode data.
Statistical analyses
Statistical analyses between two groups were performed with an unpaired Student t-test and probability (P) values were calculated.
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